The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Racing to Shorten Duration of Hep C Treatment

Back to News Homepage

Next

Can This Virus Prevent Liver Transplant Rejection?

Which Big Name Protease Inhibitor Left the Hepatitis C Market?

Print this page

Find out why Germany’s Boehringer Ingelheim has stopped development of faldepravir, its lead candidate in the HCV market.

Boehringer pulls faldepravir and exits hepatitis C market

Unable to challenge all-oral options from Gilead and others

Germany’s Boehringer Ingelheim is bowing out of the race to develop oral hepatitis C virus (HCV) therapies and has discontinued development of lead candidate faldepravir.

After a strategic review of its business, the company said it had elected to withdraw all regulatory filings for faldepravir – a protease inhibitor – because the “HCV treatment environment has significantly and rapidly evolved” in the last couple of years.

Continue reading this entire article:
http://www.pmlive.com/pharma_news/boehringer_pulls_faldepravir_and_exits_hcv_market_580066

1 Comment
Share
Share

Previous

Racing to Shorten Duration of Hep C Treatment

Back to News Homepage

Next

Can This Virus Prevent Liver Transplant Rejection?

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.